2024
Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I , et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045 .
View Abstract
Publication: Manuscripts
Minshall ME, Liu Y, Wagner A, Jensen IS , Corman S. The cost for of chronic lung allograft dysfunction (CLAD) in lung transplant (LTX) recipients by stage 1-4: A claims database analysis. Abstract EE70 . ISPOR 2024.
View Abstract
Publication: Abstracts and Presentations
2023
Garrison K, Zhang W, Jensen I , Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Jensen I , Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539 . ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258 .
Publication: Abstracts and Presentations
2022
Jensen I , Cyr P . 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive .
Publication: White paper
Yao W, Jensen I , Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi: 10.5863/1551-6776-27.8.695 .
View Abstract
Publication: Manuscripts
Pang F, Dean R, Jensen I , Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24 . ISPOR 2022.
View Abstract
Publication: Abstracts and Presentations
2021
Pang F, Dean R, Jensen I , Olaye A, Miller B. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Abstract PRO30 . ISPOR 2021.
View Abstract
Publication: Abstracts and Presentations
2014
Jensen IS , Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin lymphoma in the United States: A budgetary impact analysis. Abstract C14 . Academy of Managed Care Pharmacy 26th Annual Meeting & Expo 2014.
A Division of